- Home
- DHF vs TIL Comparison
DHF vs TIL Comparison
Compare DHF & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DHF | TIL |
|---|---|---|
| Founded | 1998 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 185.7M | 74.7M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | DHF | TIL |
|---|---|---|
| Price | $2.52 | $7.06 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $125.00 |
| AVG Volume (30 Days) | ★ 451.1K | 257.8K |
| Earning Date | 01-01-0001 | 03-03-2026 |
| Dividend Yield | ★ 7.65% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.06 | $5.67 |
| 52 Week High | $2.39 | $42.79 |
Technical Indicators
Market Signals| Indicator | DHF | TIL |
|---|---|---|
| Relative Strength Index (RSI) | 50.57 | 31.51 |
| Support Level | $2.47 | $6.91 |
| Resistance Level | $2.54 | $7.31 |
| Average True Range (ATR) | 0.02 | 0.65 |
| MACD | 0.00 | -0.15 |
| Stochastic Oscillator | 63.63 | 20.24 |
Price Performance
Historical ComparisonAbout DHF BNY Mellon High Yield Strategies Fund
BNY Mellon High Yield Strategies Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income and its secondary objective is capital appreciation. The fund invests predominantly in fixed-income securities of below-investment-grade credit quality.
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.